Edition:
United Kingdom

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

10.47USD
9:00pm BST
Change (% chg)

$-0.12 (-1.13%)
Prev Close
$10.59
Open
$10.60
Day's High
$10.64
Day's Low
$10.33
Volume
32,077
Avg. Vol
84,149
52-wk High
$22.53
52-wk Low
$5.42

Chart for

About

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which... (more)

Overall

Beta: --
Market Cap(Mil.): $128.07
Shares Outstanding(Mil.): 13.26
Dividend: --
Yield (%): --

Financials

  ZYNE.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -2.62 -- --
ROI: -55.80 1.58 14.38
ROE: -55.80 2.41 16.07

BRIEF-Zynerba Pharmaceuticals Says ZYN002 Was Shown To Be Well Tolerated Through 12 Months Of Treatment In Star 2 Study

* ZYNERBA PHARMACEUTICALS SAYS ZYN002 WAS SHOWN TO BE WELL TOLERATED THROUGH 12 MONTHS OF TREATMENT IN STAR 2

25 Apr 2018

BRIEF-Zynerba Pharmaceuticals Appoints John P. Butler To Board Of Directors

* ZYNERBA PHARMACEUTICALS APPOINTS JOHN P. BUTLER TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

16 Apr 2018

BRIEF-Zynerba Pharmaceuticals Initiates Open Label Phase 2 Trial Of ZYN002 In Developmental And Epileptic Encephalopathies (DEE)

* ZYNERBA PHARMACEUTICALS INITIATES OPEN-LABEL PHASE 2 TRIAL OF ZYN002 IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEE)

10 Apr 2018

BRIEF-Zynerba Pharmaceuticals Reports Q4 Loss Per Share $0.60

* ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

12 Mar 2018

BRIEF-Zynerba Pharma Plans To Conduct Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support NDA Filing

* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION AND PLANS TO CONDUCT A SINGLE PIVOTAL STUDY OF ZYN002 IN FRAGILE X SYNDROME TO SUPPORT AN NDA FILING

05 Mar 2018

BRIEF-Zynerba Pharmaceuticals Inc ‍Plans To Initiate Phase 2 Development Of ZYN001 In Tourette Syndrome By Year End ​

* ZYNERBA PHARMACEUTICALS PROVIDES 2018 CLINICAL AND CORPORATE UPDATE

03 Jan 2018

BRIEF-Zynerba Pharmaceuticals reports Q3 loss per share of $0.63

* Zynerba Pharmaceuticals reports third quarter 2017 financial results and operational highlights

14 Nov 2017

Earnings vs. Estimates